Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy

Takehiro Kawashiri, Mizuki Inoue, Kohei Mori, Daisuke Kobayashi, Keisuke Mine, Soichiro Ushio, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Takao Shimazoe

研究成果: Contribution to journalReview article査読

抄録

Paclitaxel is an essential drug in the chemotherapy of ovarian, non-small cell lung, breast, gastric, endometrial, and pancreatic cancers. However, it frequently causes peripheral neuropathy as a dose-limiting factor. Animal models of paclitaxel-induced peripheral neuropathy (PIPN) have been established. The mechanisms of PIPN development have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory PIPN effects. This review summarizes the basic and clinical evidence for therapeutic or prophylactic effects for PIPN. In pre-clinical research, many reports exist of neuropathy inhibitors that target oxidative stress, inflammatory response, ion channels, transient receptor potential (TRP) channels, cannabinoid receptors, and the monoamine nervous system. Alternatively, very few drugs have demonstrated PIPN efficacy in clinical trials. Thus, enhancing translational research to translate pre-clinical research into clinical research is important.

本文言語英語
論文番号8733
ジャーナルInternational journal of molecular sciences
22
16
DOI
出版ステータス出版済み - 8 2 2021

All Science Journal Classification (ASJC) codes

  • 触媒
  • 分子生物学
  • 分光学
  • コンピュータ サイエンスの応用
  • 物理化学および理論化学
  • 有機化学
  • 無機化学

フィンガープリント

「Preclinical and clinical evidence of therapeutic agents for paclitaxel-induced peripheral neuropathy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル